FDA Approved: VIVELLE-DOT — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved a supplemental application for VIVELLE-DOT (estradiol) filed by Sandoz, resulting in labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis
• Vasomotor Symptoms of Menopause

Drugs mentioned

• VIVELLE-DOT (ESTRADIOL)

Snippet

SUPPL AP for VIVELLE-DOT (ESTRADIOL)